Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.
Deegen P, Thomas O, Nolan-Stevaux O, Li S, Wahl J, Bogner P, Aeffner F, Friedrich M, Liao MZ, Matthes K, Rau D, Rattel B, Raum T, Kufer P, Coxon A, Bailis JM. Deegen P, et al. Among authors: nolan stevaux o. Clin Cancer Res. 2021 May 15;27(10):2928-2937. doi: 10.1158/1078-0432.CCR-20-3725. Epub 2021 Jan 27. Clin Cancer Res. 2021. PMID: 33504551
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL, Fajardo F, Zhong W, Bernett MJ, Muchhal US, Moore GL, Stevens J, Case R, Pearson JT, Liu S, McElroy PL, Canon J, Desjarlais JR, Coxon A, Balazs M, Nolan-Stevaux O. Zuch de Zafra CL, et al. Among authors: nolan stevaux o. Clin Cancer Res. 2019 Jul 1;25(13):3921-3933. doi: 10.1158/1078-0432.CCR-18-2752. Epub 2019 Mar 27. Clin Cancer Res. 2019. PMID: 30918018
Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors.
Belmontes B, Sawant DV, Zhong W, Tan H, Kaul A, Aeffner F, O'Brien SA, Chun M, Noubade R, Eng J, Ma H, Muenz M, Li P, Alba BM, Thomas M, Cook K, Wang X, DeVoss J, Egen JG, Nolan-Stevaux O. Belmontes B, et al. Among authors: nolan stevaux o. Sci Transl Med. 2021 Aug 25;13(608):eabd1524. doi: 10.1126/scitranslmed.abd1524. Sci Transl Med. 2021. PMID: 34433637
Characterization of an Anti-CD70 Half-Life Extended Bispecific T-Cell Engager (HLE-BiTE) and Associated On-Target Toxicity in Cynomolgus Monkeys.
Harper T, Sharma A, Kaliyaperumal S, Fajardo F, Hsu K, Liu L, Davies R, Wei YL, Zhan J, Estrada J, Kvesic M, Nahrwold L, Deisting W, Panzer M, Cooke K, Lebrec H, Nolan-Stevaux O. Harper T, et al. Among authors: nolan stevaux o. Toxicol Sci. 2022 Aug 25;189(1):32-50. doi: 10.1093/toxsci/kfac052. Toxicol Sci. 2022. PMID: 35583313
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
Nolan-Stevaux O, Li C, Liang L, Zhan J, Estrada J, Osgood T, Li F, Zhang H, Case R, Murawsky CM, Estes B, Moore GL, Bernett MJ, Muchhal U, Desjarlais JR, Staley BK, Stevens J, Cooke KS, Aeffner F, Thomas O, Stieglmaier J, Lee JL, Coxon A, Bailis JM. Nolan-Stevaux O, et al. Cancer Discov. 2024 Jan 12;14(1):90-103. doi: 10.1158/2159-8290.CD-23-0984. Cancer Discov. 2024. PMID: 37861452
11 results